CAS 1155866-55-9

Formula: C48H70N10O12

InChI: InChI=1S/C48H70N10O12/c1-26(2)23-35(53-38(59)24-31-17-19-32(20-18-31)52-48(70)56-33-14-9-8-13-28(33)5)43(64)55-36(25-39(60)61)44(65)57-40(27(3)4)46(67)58-22-12-16-37(58)45(66)51-29(6)41(62)50-30(7)42(63)54-34(47(68)69)15-10-11-21-49/h8-9,13-14,17-20,26-27,29-30,34-37,40H,10-12,15-16,21-25,49H2,1-7H3,(H,50,62)(H,51,66)(H,53,59)(H,54,63)(H,55,64)(H,57,65)(H,60,61)(H,68,69)(H2,52,56,70)/t29-,30-,34-,35-,36-,37-,40-/m0/s1

InChI key: FQYZPSNPTJYQKB-CGTMUHGOSA-N

SMILES: CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O

Calcineurin substrate acetate

CAS: 1155866-55-9

Calcineurin substrate acetate

Formula: C₉₄H₁₅₄N₂₈O₃₁

Purity: 97.5%

Molecular weight: 2172.4

Ref: 54-BUP20475

LDV

CAS: 1155866-55-9

α4β1 integrin (VLA-4) ligand (Kd ~ 12 nM). Non-fluorescent derivative of LDV FITC.

Formula: C₄₈H₇₀N₁₀O₁₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 979.1292

Ref: TM-TP2006

N-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-leucyl-L-α-aspartyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-L-lysine

CAS: 1155866-55-9

Formula: C₄₈H₇₀N₁₀O₁₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 979.1292

Ref: IN-DA01LSX2

LDV

CAS: 1155866-55-9

LDV is a drug that is used to treat chronic viral hepatitis. It belongs to the class of drugs known as nucleoside analogues and inhibits the replication of the virus by blocking DNA synthesis. LDV has been shown to be effective for treating chronic hepatitis B, chronic hepatitis C, and human immunodeficiency virus (HIV) infection. LDV is metabolized by the liver into its active form, tenofovir. LDV can cause liver impairment and has drug interactions with other drugs. LDV also causes thermal expansion in plastics such as PVC tubing used for dialysis equipment.

Formula: C₄₈H₇₀N₁₀O₁₂

Purity: Min. 95%

Molecular weight: 979.1 g/mol

Ref: 3D-FWB86655